⌘K

TSBX

NASDAQ

Turnstone Biologics Corp.

SectorHealth CareIndustryBiotechnology: Biological Products (No Diagnostic Substances)IPO2023

News25/Ratings6

Latest news

25 items

245dSEC
SEC Form 15-12G filed by Turnstone Biologics Corp.
15-12G - Turnstone Biologics Corp. (0001764974) (Filer)
254dINSIDER
SEC Form 4 filed by Director Orbimed Advisors Llc
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
254dSEC
Amendment: SEC Form SCHEDULE 13D/A filed by Turnstone Biologics Corp.
SCHEDULE 13D/A - Turnstone Biologics Corp. (0001764974) (Subject)
254dINSIDER
SEC Form 4 filed by Large owner Versant Ventures V, Llc
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
255dSEC
SEC Form S-8 POS filed by Turnstone Biologics Corp.
S-8 POS - Turnstone Biologics Corp. (0001764974) (Filer)
255dSEC
SEC Form S-8 POS filed by Turnstone Biologics Corp.
S-8 POS - Turnstone Biologics Corp. (0001764974) (Filer)
255dSEC
Turnstone Biologics Corp. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant
8-K - Turnstone Biologics Corp. (0001764974) (Filer)
255dSEC
Amendment: SEC Form SC 14D9/A filed by Turnstone Biologics Corp.
SC 14D9/A - Turnstone Biologics Corp. (0001764974) (Subject)
255dSEC
SEC Form 25-NSE filed by Turnstone Biologics Corp.
25-NSE - Turnstone Biologics Corp. (0001764974) (Subject)
255dSEC
Amendment: SEC Form SC TO-T/A filed by Turnstone Biologics Corp.
SC TO-T/A - Turnstone Biologics Corp. (0001764974) (Subject)
255dPR
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
- Turnstone Stockholders Received $0.34 Per Share in Cash Plus Contingent Value Right - EMERYVILLE, Calif., Aug. 11, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ:XOMA) ("XOMA Royalty" or the "Company"), a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health, today announced the Company has successfully completed its previously announced tender offer to acquire all outstanding shares of Turnstone Biologics Corp. (NASDAQ:TSBX) common stock for a price per share of $0.34 in cash (the "Cash Amount"), plus one non-tradeable contingent value right ("CVR" and together with the Cash Amount, the "Offer Pr
258dSEC
SEC Form 10-Q filed by Turnstone Biologics Corp.
10-Q - Turnstone Biologics Corp. (0001764974) (Filer)
258dINSIDER
SEC Form 4 filed by Director Jerel Davis
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
258dINSIDER
SEC Form 4 filed by Director Gupta Rishi
4 - Turnstone Biologics Corp. (0001764974) (Issuer)
280dSEC
Amendment: SEC Form SC 14D9/A filed by Turnstone Biologics Corp.
SC 14D9/A - Turnstone Biologics Corp. (0001764974) (Subject)
280dSEC
Amendment: SEC Form 8-K/A filed by Turnstone Biologics Corp.
8-K/A - Turnstone Biologics Corp. (0001764974) (Filer)
286dSEC
SEC Form SC 14D9 filed by Turnstone Biologics Corp.
SC 14D9 - Turnstone Biologics Corp. (0001764974) (Subject)
286dSEC
SEC Form SC TO-T filed by Turnstone Biologics Corp.
SC TO-T - Turnstone Biologics Corp. (0001764974) (Subject)
296dSEC
Amendment: SEC Form 8-K/A filed by Turnstone Biologics Corp.
8-K/A - Turnstone Biologics Corp. (0001764974) (Filer)
300dSEC
Turnstone Biologics Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure
8-K - Turnstone Biologics Corp. (0001764974) (Filer)
300dSEC
SEC Form SC14D9C filed by Turnstone Biologics Corp.
SC14D9C - Turnstone Biologics Corp. (0001764974) (Subject)
300dSEC
SEC Form SC TO-C filed by Turnstone Biologics Corp.
SC TO-C - Turnstone Biologics Corp. (0001764974) (Subject)
300dPR
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
EMERYVILLE, Calif. and SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation ("XOMA Royalty") (NASDAQ:XOMA) and Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX) today announced that they have entered into a definitive merger agreement ("the Merger Agreement"), whereby XOMA Royalty will acquire Turnstone for $0.34 in cash per share of Turnstone common stock ("Turnstone common stock") plus one non-transferable contingent value right ("CVR"). Following a thorough review process conducted with the assistance of its legal and financial advisors, the Turnstone Board of Directors has unanimously determined that the acquisition by XOMA Royalty is in the best
346dSEC
Amendment: SEC Form SCHEDULE 13G/A filed by Turnstone Biologics Corp.
SCHEDULE 13G/A - Turnstone Biologics Corp. (0001764974) (Subject)
350dPR
Turnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate Highlights
SAN DIEGO, May 08, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a biotechnology company historically focused on the development of a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte ("Selected TIL") therapy, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. Corporate Updates In January 2025, Turnstone made the determination to discontinue all TIDAL-01 clinical studies and halted further development of the program. As a result, the Company initiated a process to explore a range of potentia